[PDF] Top 20 A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus

... CV safety studies for the daily DPP-4 inhibitors saxagliptin (SAVOR-TIMI 53), alogliptin (EXAMINE) and sitagliptin (TECOS) have been completed and the results of these studies have significantly ... See full document

... N. Inagaki has received consulting fees and research support from Mitsubishi Tanabe Pharma Corp., and has served on speakers bureaus for Mitsubishi Tanabe Pharma Corp. He has also received consulting fees and/or research ... See full document

... present study demonstrated that in patients with T2D and inadequate glycemic control with the combin- ation of metformin (≥1500 mg/day) and glimepiride (≥4 mg/day), treatment with omarigliptin ... See full document

... This randomized, double-blind, placebo-controlled study enrolled participants with a baseline A1c of between ...were randomized to continue metformin therapy in addition to either ... See full document

... that patients received needed glycemic ...fewer patients were able to contribute data for efficacy analyses at later time points in the ...of patients with available effi- cacy data at later time ... See full document

... with type-1 diabetes mellitus, who had previously been treated with sitagliptin or had previously been in a study using a DPP-4 inhibitor, alcoholic patients, ... See full document

... the safety and efficacy of adding sitagliptin to ongoing metformin therapy (1500 mg/day) in patients with a mean A1c of ...8.0%. Patients were randomized to receive sitagliptin 100 mg daily ... See full document

... although DPP-4 inhibitors are “insulin secretagogues”, they are expected to improve beta cell func- tion in addition to having a glucose-lowering effect and other advantages, as described in Table ...of ... See full document

... the placebo, alogliptin ...of patients across the treatment groups ...0.8%; placebo: ...with placebo, ...with placebo, ...with placebo, ...with placebo and ... See full document

... “diabetes mellitus”, “type 2 diabetes”, or “noninsulin-dependent diabetes mellitus”; “sita- gliptin”; and “randomized controlled trials”, “clinical trials”, ... See full document

... trials, patients receiving sitagliptin–metformin com- bination therapy generally maintained their weight or lost an average of up to ...that patients with poorly controlled diabetes at ... See full document

... for patients with inadequate glycemic control on metformin ...and patients’ quality of life and safety need to be carefully con- sidered when ...a cardiovascular history and ...of type ... See full document

... past 2 decades, most possibly due to increasing maternal obesity and aging mothers at first pregnancy (Duran et al ...and safety are not well-understood ... See full document

... some DPP-4 inhibitors and HF will require additional trials and potentially more ...the DPP-4 class effects on biomarkers, which propagates through to our final event rate ...of ... See full document

... day 2 through day 4, 20 mg of teneligliptin was also taken, before breakfast, in addition to ...(days 2 to ...1, 2, 3, and 4 were 142 ± 26, 145 ± 20, 135 ± 15, and 126 ± 16 mg/dL, ... See full document

... in patients with contraindications to metformin or metformin intol- erance, and in combination with other oral compounds and/or ...insulin. DPP-4 inhibitors act in a glucose-dependent manner and only ... See full document

... (DPP-4) inhibitor class of drugs represents one of the newest groups available for diabetes ...Two DPP-4 inhibitors are currently available in the United States: sitagliptin and ... See full document

... in patients with T2DM; biguanides (eg, metformin), insulin secretagogues (eg, sulfonylureas), thiazolidinediones, alpha glycosidase inhibitors, and DPP-4 ... See full document

... Abstract: Exenatide has been widely used for the treatment of type 2 diabetes mellitus. However, its short plasma half-life of 2.4 hours has limited its clinical application. The exenatide ... See full document

... between cardiovascular disease risk factors and the earliest event in the cascade of incidents that results in target organ ...in patients with hypertension, ventricular hypertrophy, diabetes ... See full document